

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



Dorset
Clinical Commissioning Group

The Dorset Medicines Advisory Group (DMAG) represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 21st January 2020. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
1. Products re-categorised	Previous position	Recommended position	
Erythromycin	Amber	Green	In section 05.01.05 as an option for various indications for children, pregnant or breastfeeding women in line with SCAN and NICE guidelines
Ciprofloxacin ear drops (single use) 2mg/ml Cetraxal®	Red	Green	As a second line choice only in primary care, based on sensitivities.
Pentosan polysulfate sodium	Non-Formulary	Red	In line with NICE TA610 for the use of Pentosan polysulfate sodium for treating bladder pain syndrome.
2. New requests			
Ivabradine	Amber with SCG		Ivabradine for use in postural orthostatic tachycardia syndrome (POTS) or inappropriate sinus tachycardia (IST)
Syreni Ring®	Amber		This is the same hormonal form as Nuvaring® but there is a more gradual release of hormone, and it is not necessary to refrigerate whilst being more cost-effective.
ketotifen P/F eye drops	Green		A second line option after the use of sodium cromoglicate

PRODUCT	DECISION	COMMENTS
Fluocinolone acetonide intravitreal implant	Non-Formulary (for this indication)	In line with NICE TA613 the use of Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy. The implant is not recommended for this indication
3. Products considered by NICE		
NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome NICE TA613 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy.		
4. Miscellaneous recommendations by DMAG		
Amantadine	Amended wording	To not recommended for prophylaxis in line with NICE TA158
Acetic Acid 2% spray	Note to be added	DMAG approved that a note is added to the formulary entry to say it is available as a first line treatment of superficial external ear infections, but is to be purchased over the counter
Evicel®	Red	A thrombin sealant for use in robotic partial nephrectomies, approved for use by RBCH/PHT Joint D&TC
Sevikar®-HCT	To remain non formulary	
The European Society of Cardiology (Dual antiplatelet therapy and percutaneous coronary intervention) in patients with coronary artery disease Guidance	Link to be added	The group Approved the adoption of the guidance from the European Society of Cardiology (Dual antiplatelet therapy and percutaneous coronary intervention) in patients with coronary artery disease
5. Further Assessment / Evidence Required		

PRODUCT	DECISION	COMMENTS
VTE prophylaxis LMWH in renal impairment	Further discussion needed with nephrology.	Although this has been approved by the cardiologists and a haematologist the group felt because it had not been discussed with the nephrology service it couldn't be approved
6. New documents approved		
Investigation and treatment of Adult Vitamin B12 (Cobalamin) Deficiency Guideline.		
7. Documents Reviewed		
Ivabradine Shared Care Guideline (Heart failure, Angina and in postural orthostatic tachycardia syndrome (POTS) or inappropriate sinus tachycardia (ITS)) The Stoma Ancillary products Formulary Review Guidance document. The hydroxycarbamide shared care guideline		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset